Non-Steroidal Anti-Inflammatory Drugs in Acute Myocarditis

Last updated: February 12, 2026
Sponsor: Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III
Overall Status: Active - Recruiting

Phase

3

Condition

Dermatomyositis (Connective Tissue Disease)

Chest Pain

Treatment

ibuprofen

Clinical Study ID

NCT06686862
2024-513803-15-00
2024-513803-15-00
  • Ages > 18
  • All Genders

Study Summary

Prospective, randomized, multicenter, open-label clinical trial to evaluate the safety and efficacy of a 3-week ibuprofen tapering regimen compared to conventional analgesic treatment (acetaminophen) in patients with acute myocarditis and left ventricular ejection fraction ≥50%. The objective is to assess the reduction in late gadolinium enhancement on cardiac magnetic resonance imaging at 6-month follow-up.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Aged 18 years or older.

  • Patients hospitalized for confirmed acute myocarditis and left ventricular ejectionfraction ventricular >50%.

  • Elevated troponin I/T (3 times above the upper limit of normal).

  • Absence of acute heart failure.

  • Absence of ischemic heart disease (ruled out by coronary angiography or coronary CTin individuals over 40 years).

  • Diagnostic criteria for myocarditis (Lake Louise, 2018 update) by cardiac magneticresonance imaging.

Exclusion

Exclusion Criteria:

  • Kidney disease stage 3b, 4 and 5 (creatinine clearance by CKD-EPI <45 ml/min/1.73m2).

  • Severe liver failure (Child-Pugh class C).

  • Poorly controlled pharmacological hypertension (repeatedly systolic arterialpressure >140 mmHg).

  • Diagnosis criteria for acute pericarditis.

  • Moderate or severe pericardial effusion (>10 mm in total).

  • Hypersensitivity to NSAIDs or previous use in the last 7 days.

  • Contraindication for MRI.

  • Participation in another clinical trial.

  • Pregnancy, breastfeeding, or women of childbearing age unwilling to use appropriatecontraception throughout the study.

  • Any circumstance that, in the investigator's opinion, compromises participation inthe clinical trial.

Study Design

Total Participants: 150
Treatment Group(s): 1
Primary Treatment: ibuprofen
Phase: 3
Study Start date:
April 28, 2025
Estimated Completion Date:
October 31, 2027

Study Description

The treatment for patients with uncomplicated myocarditis (left ventricular ejection fraction >50% without heart failure) is not currently well defined. Analgesic drugs are commonly used to manage pain. The use of nonsteroidal anti-inflammatory drugs (NSAIDs) among analgesics is controversial due to potential harmful effects observed in animal models. However, NSAIDs are the standard treatment for pericarditis, even when it is associated with mild myocardial involvement. In patients with acute myocarditis and normal left ventricular ejection fraction, observational studies have suggested that NSAIDs may have a beneficial effect in reducing late gadolinium enhancement (LGE) measured in cardiac magnetic resonance (CMR), an important prognostic marker in this population.

We plan to conduct a prospective, randomized, multicenter, open-label clinical trial to evaluate the safety and efficacy of NSAIDs versus conventional analgesic treatment in patients with uncomplicated acute myocarditis and left ventricular ejection fraction ≥50%.

Approximately 150 patients will be randomized 1:1 to NSAID treatment (ibuprofen tapering schedule during 3 weeks) or conventional treatment (acetaminophen or metamizole in case of allergy until pain resolution) during hospital admission. Patients will be followed for a 12-month period. Baseline CMR will be performed at initial hospitalization for acute myocarditis and at 3 and 6 months.

The primary objective is to assess the utility of ibuprofen versus conventional treatment with analgesics in acute myocarditis with preserved LVEF, in terms of reducing LGE on CMR at 6-month follow-up compared to baseline.

Connect with a study center

  • Hospital Universitario Puerta de Hierro-Majadahonda

    Majadahonda, Madrid 28222
    Spain

    Site Not Available

  • Hospital Universitario Puerta de Hierro-Majadahonda

    Majadahonda 3117667, Madrid 3117732 28222
    Spain

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.